
Loading, please wait...

Loading, please wait...

Recent research in Nature Neuroscience clarifies how Neuropeptide Y memory extinction mechanisms operate within the brain’s hippocampal circuitry. Specifically, scientists discovered that neuropeptide Y (NPY)-expressing interneurons in the ventral CA1 (vCA1) region play a dual role. These neurons utilize fast GABA-ergic inhibition to help acquire memories. Conversely, they employ slow NPY-mediated inhibition to promote memory extinction. Consequently, this intricate process determines whether a memory remains stable or becomes malleable over time.
Moreover, researchers observed that calcium dynamics and NPY release ramp up significantly as the behavioral state switches from fear to safety. This biochemical shift is essential for successful extinction learning. By acting on non-overlapping subensembles of NPY1R- and NPY2R-expressing neurons, the peptide gates different stages of the extinction process. Therefore, these receptors serve as critical regulators of both early fast and late slow stages of behavioral adaptation.
Understanding these mechanisms provides a potential framework for treating disorders like PTSD. In addition, the study suggests that NPY is both necessary and sufficient for controlling memory extinction rates. By targeting specific NPY receptor subensembles, clinicians might eventually develop precision therapies for maladaptive fear. Thus, this neurobiological breakthrough offers hope for more effective interventions in psychiatric medicine. Similarly, future studies may explore if these pathways function identically in humans to validate these therapeutic targets.
NPY facilitates extinction by providing slow peptidergic inhibition through NPY1R and NPY2R receptors. This process helps the brain transition from a fearful state to a non-fearful one during learning sessions.
The ventral CA1 (vCA1) is a critical hub for emotional memory. It contains specific interneurons that manage the stability of fear memories and determine the rate at which they are extinguished.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional clinical judgment. Refer to the latest local and national guidelines for clinical practice.
References
Wu YJ et al. Neuropeptide Y co-opts neuronal ensembles for memory lability and stability. Nat Neurosci. 2026 Mar 31. doi: 10.1038/s41593-026-02235-x. PMID: 41917464.
Sah P, Geracioti TD. Neuropeptide Y and posttraumatic stress disorder. Mol Psychiatry. 2013;18(6):646-655.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A Nature Neuroscience study reveals how Neuropeptide Y interneurons in the hippocampus control memory extinction via specific receptor-expressing ensembles....
6 months ago

As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today